Immunotherapy for acute lymphoblastic leukemia: from famine to feast
نویسندگان
چکیده
منابع مشابه
Immunotherapy for acute lymphoblastic leukemia: from famine to feast.
Publisher's Note: This article has a companion Point by Jabbour and Kantarjian. Publisher's Note: Join in the discussion of these articles at Blood Advances Community Conversations.
متن کاملLeukemia cell-rhabdovirus vaccine: personalized immunotherapy for acute lymphoblastic leukemia.
PURPOSE Acute lymphoblastic leukemia (ALL) remains incurable in most adults. It has been difficult to provide effective immunotherapy to improve outcomes for the majority of patients. Rhabdoviruses induce strong antiviral immune responses. We hypothesized that mice administered ex vivo rhabdovirus-infected ALL cells [immunotherapy by leukemia-oncotropic virus (iLOV)] would develop robust antile...
متن کاملFeast or famine
Lysosomal storage diseases are metabolic disorders characterized by the accumulation of acidic vacuoles, and are usually the consequence of the deficiency of an enzyme responsible for the metabolism of vesicular lipids, proteins or carbohydrates. In contrast, mucolipidosis type IV (MLIV), results from the absence of a vesicular Ca ( 2+) release channel called mucolipin 1/transient receptor pot...
متن کاملRecent Developments in Immunotherapy for Acute Lymphoblastic Leukemia
Despite high rates of initial response to frontline therapy, the prognosis of adult patients with acute lymphoblastic leukemia (ALL) is still unsatisfactory, as many of them fail to reach a stable complete molecular response and they ultimately relapse. Intensification of chemotherapy regimens has determined a survival improvement especially in younger patients, but this strategy is less effect...
متن کاملT-cell adoptive immunotherapy for acute lymphoblastic leukemia.
Substantial progress has been made in the treatment of precursor B-cell acute lymphoblastic leukemia (B-ALL), but recurrent disease remains a leading cause of death in children due to cancer and outcomes for adults with B-ALL remain poor. Recently, complete clinical responses have been observed in small numbers of patients with B-ALL treated with adoptive immunotherapy using T cells genetically...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Blood Advances
سال: 2016
ISSN: 2473-9529,2473-9537
DOI: 10.1182/bloodadvances.2016000034